Trial reportDrug and alcohol dependence2007
Bupropion SR for the treatment of smokeless tobacco use.
Trial report in Drug and alcohol dependence, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 6 syntheses or guidelines pooled it.
- Interventions for smokeless tobacco use cessation.The Cochrane database of systematic reviews · 2025Pooled it
- Efficacy of pharmacological intervention for smokeless tobacco cessation in adults: a systematic review and meta-analysis.Archives of public health = Archives belges de sante publique · 2025Pooled it
- Antidepressants for smoking cessation.The Cochrane database of systematic reviews · 2020Pooled it
- Smokeless tobacco cessation interventions: A systematic review.The Indian journal of medical research · 2018Pooled it
- Interventions for smokeless tobacco use cessation.The Cochrane database of systematic reviews · 2015Pooled it
- Antidepressants for smoking cessation.The Cochrane database of systematic reviews · 2014Pooled it
- Randomized trial of nicotine lozenges and phone counseling for smokeless tobacco cessation.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2015Trial
- A double-blind placebo-controlled randomized trial of varenicline for smokeless tobacco dependence in India.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2014Trial
- A randomized phase II clinical trial of high-dose nicotine patch therapy for smokeless tobacco users.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2013Trial
- A comparison of three smokeless tobacco dependence measures.Addictive behaviors · 2012Trial
- Comparing an immediate cessation versus reduction approach to smokeless tobacco cessation.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2012Trial
- A randomized clinical trial of nicotine lozenge for smokeless tobacco use.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2009Trial
- Predictors of smokeless tobacco abstinence.American journal of health behaviorTrial
- The Effects of Alpha Linolenic Acid (Omega-3 Fatty Acid) on Tobacco Craving Intensity, Withdrawal Symptoms and Biochemical Markers in Tobacco Users.Indian journal of clinical biochemistry : IJCB · 2025Article
- Article
- Antidepressants for smoking cessation.The Cochrane database of systematic reviews · 2023Review
- Review
- Treating tobacco dependence in a medical setting.CA: a cancer journal for cliniciansArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundNo pharmacotherapies have been shown to increase long-term (> or = 6 months) tobacco abstinence rates among smokeless tobacco (ST) users. Bupropion SR has demonstrated potential efficacy for ST users in pilot studies. We conducted a multicenter, randomized, double-blind, placebo-controlled, clinical trial to assess the efficacy and safety of bupropion SR for tobacco abstinence among ST users.
methodsAdult ST users were randomized to bupropion SR titrated to 150 mg twice daily (N=113) or placebo (N=112) for 12 weeks plus behavioral intervention. The primary endpoint was the 7-day point-prevalence tobacco abstinence rate at week 12. Secondary outcomes included prolonged and continuous tobacco abstinence rates, craving and nicotine withdrawal, and weight gain.
resultsThe 7-day point-prevalence tobacco abstinence rates did not differ between bupropion SR and placebo at the end treatment (53.1% versus 46.4%; odds ratio (OR) 1.3; p=0.301). The 7-day point-prevalence abstinence did not differ at weeks 24 and 52. The prolonged and continuous tobacco abstinence rates did not differ at weeks 12, 24, and 52. A time-by-treatment interaction was observed in craving over time with greater decreases in the bupropion SR group. At 12 weeks, the mean (+/-S.D.) weight change from baseline among abstinent subjects was an increase of 1.7 (+/-2.9)kg for the bupropion SR group compared to 3.2 (+/-2.7)kg for placebo (p=0.005).
conclusionsBupropion SR did not significantly increase tobacco abstinence rates among ST users, but it significantly decreased craving and weight gain over the treatment period.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.